{"id":"comparator-celecoxib","safety":{"commonSideEffects":[{"rate":"8-15","effect":"Dyspepsia"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Hypertension"},{"rate":"1-3","effect":"Cardiovascular events (myocardial infarction, stroke)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Celecoxib is a selective COX-2 inhibitor that preferentially blocks COX-2 over COX-1, thereby reducing inflammatory prostaglandins while theoretically sparing the protective prostaglandins produced by COX-1 in the gastrointestinal tract. This selectivity was designed to provide anti-inflammatory and analgesic efficacy with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs.","oneSentence":"Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:43.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Acute pain"},{"name":"Familial adenomatous polyposis (FAP)"}]},"trialDetails":[{"nctId":"NCT05488847","phase":"PHASE4","title":"Opioid-Free Pain Protocol After Shoulder Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henry Ford Health System","startDate":"2022-06-25","conditions":"Shoulder Arthropathy, Shoulder Pain","enrollment":83},{"nctId":"NCT00092768","phase":"PHASE3","title":"A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03-01","conditions":"Osteoarthritis","enrollment":500},{"nctId":"NCT00092781","phase":"PHASE3","title":"A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03-01","conditions":"Osteoarthritis","enrollment":500},{"nctId":"NCT05555823","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib","status":"COMPLETED","sponsor":"Atriva Therapeutics GmbH","startDate":"2022-06-23","conditions":"Healthy","enrollment":96},{"nctId":"NCT05324163","phase":"PHASE3","title":"Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis","status":"COMPLETED","sponsor":"Jiangsu XinChen-Techfields Pharma Co., LTD.","startDate":"2021-09-29","conditions":"KNEE OSTEOARTHRITIS","enrollment":180},{"nctId":"NCT03304379","phase":"PHASE3","title":"Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-10-26","conditions":"Osteoarthritis, Knee, Osteoarthritis, Hip","enrollment":1650},{"nctId":"NCT05362851","phase":"PHASE3","title":"Clinical Trial of YYC301 P3 for Treatment of Osteoarthritis of the Knee","status":"UNKNOWN","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2021-11-11","conditions":"Osteoarthritis, Knee","enrollment":692},{"nctId":"NCT01554163","phase":"PHASE3","title":"Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-03","conditions":"Osteoarthritis of the Knee","enrollment":239},{"nctId":"NCT04505657","phase":"NA","title":"Lidocaine Spray Plus Oral Celecoxib for Pain Control During Hysterosalpingography","status":"COMPLETED","sponsor":"Aswan University Hospital","startDate":"2020-09-01","conditions":"IUCD Complication","enrollment":150},{"nctId":"NCT03850587","phase":"PHASE2","title":"Clinical Trial of YYC301 for Treatment of Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2018-08-30","conditions":"Osteoarthritis, Knee","enrollment":261},{"nctId":"NCT00585312","phase":"PHASE3","title":"Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-09","conditions":"Adenomatous Polyposis Coli","enrollment":106},{"nctId":"NCT04082715","phase":"PHASE2","title":"Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity","status":"WITHDRAWN","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2019-10","conditions":"Chronic Back Pain","enrollment":""},{"nctId":"NCT02037165","phase":"PHASE1","title":"Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-01-21","conditions":"Healthy","enrollment":25},{"nctId":"NCT02084511","phase":"PHASE1","title":"Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-03","conditions":"Pain, Postoperative","enrollment":80},{"nctId":"NCT03062644","phase":"PHASE3","title":"Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2017-04-05","conditions":"Acute Pain","enrollment":1138},{"nctId":"NCT02982161","phase":"PHASE3","title":"Efficacy and Safety in a Randomised Acute Pain Study of MR308 (Tramadol/Celecoxib).","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2016-12-28","conditions":"Acute Pain","enrollment":818},{"nctId":"NCT03282838","phase":"PHASE1","title":"Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-06-09","conditions":"Migraine","enrollment":24},{"nctId":"NCT00285649","phase":"NA","title":"Predicting Patients' Response to Spinal Manipulation","status":"COMPLETED","sponsor":"Palmer College of Chiropractic","startDate":"2004-07","conditions":"Low Back Pain","enrollment":192},{"nctId":"NCT00092352","phase":"PHASE3","title":"A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-04-29","conditions":"Osteoarthritis","enrollment":395},{"nctId":"NCT00092365","phase":"PHASE3","title":"A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-04-01","conditions":"Osteoarthritis","enrollment":413},{"nctId":"NCT00583453","phase":"PHASE2","title":"Celecoxib as a Post-tonsillectomy Pain Medication","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2007-10","conditions":"Tonsillitis","enrollment":18},{"nctId":"NCT02925806","phase":"","title":"Evaluation of Drug Utilization Patterns for Extended Release/Long Acting Opioids and Comparator Products","status":"UNKNOWN","sponsor":"ER/LA Opioid REMS Program Companies (RPC)","startDate":"","conditions":"Opioid Related Disorders, Opiate Addiction, Narcotic Abuse","enrollment":5575834},{"nctId":"NCT01425853","phase":"PHASE4","title":"Study on Efficacy and Safety of Chondroitin Sulfate + Glucosamine Hydrochloride Versus Celecoxib in Knee Osteoarthritis","status":"COMPLETED","sponsor":"Bioiberica","startDate":"2011-09","conditions":"Knee Osteoarthritis","enrollment":606},{"nctId":"NCT02355236","phase":"PHASE4","title":"Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis","status":"UNKNOWN","sponsor":"Severance Hospital","startDate":"2015-02","conditions":"Osteoarthritis","enrollment":106},{"nctId":"NCT02179645","phase":"PHASE1","title":"GRC 27864 First in Man, Single Ascending Dose Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2014-05","conditions":"Healthy","enrollment":76},{"nctId":"NCT00367315","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-09","conditions":"Knee Osteoarthritis","enrollment":1684},{"nctId":"NCT00476034","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-12","conditions":"Osteoarthritis","enrollment":1312},{"nctId":"NCT00475800","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-01","conditions":"Osteoarthritis","enrollment":833},{"nctId":"NCT00366938","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-09","conditions":"Osteoarthritis, Knee","enrollment":1464},{"nctId":"NCT01020279","phase":"PHASE1","title":"Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise","status":"COMPLETED","sponsor":"X-pert Med GmbH","startDate":"2009-10","conditions":"Musculoskeletal Pain","enrollment":82},{"nctId":"NCT00652925","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-10","conditions":"Arthritis, Juvenile Rheumatoid","enrollment":225}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3258,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: celecoxib","genericName":"Comparator: celecoxib","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}